Articles |
Presented in part at the Xth Scientific Sessions of the American College of Cardiology, Dallas, Tex, March 6-9, 1992, and published in abstract form in J Am Coll Cardiol. 1992;19:121A.
From the Vascular Research Laboratory, Department of Pathology, and The Banting and Best Diabetes Center, University of Toronto, and The Toronto Hospital, Toronto, Ontario, Canada (A.R., A.I.G.), and the UCLA Division of Cardiology, Los Angeles, Calif (A.I.F.).
Correspondence to Alistair I. Fyfe, UCLA Division of Cardiology, 47-123 CHS, 10833 Le Conte Ave, Los Angeles, CA 90024-1679. E-mail afyfe@medicine.medsch.ucla.edu.
Abstract Endothelial denudation at areas of
predilection to atherosclerosis is balanced by an
active repair process that may be inhibited under conditions of
accelerated atherosclerosis. After cardiac
transplantation, the accelerated atherosclerotic process that develops
may be enhanced by immunosuppressive agents that have nonspecific
effects on cell signaling, proliferation, and response to injury. To
study subtle effects of cyclosporine A, azathioprine, and
6
-methylprednisolone on normal endothelial repair
processes, confluent porcine endothelial monolayers
were denuded in the presence of clinically relevant concentrations of
these agents. The rate of endothelial wound repair was
compared and the effects on cell spreading, proliferation, and the
cytoskeleton assessed. 6
-Methylprednisolone at concentrations of
1.25 to 50 µmol/L was associated with a transient 30% to 60%
inhibition of endothelial wound repair. This was
associated with increased cell size at the wound edge and a delay in
centrosomal reorientation toward the wound, without any effect on cell
proliferation. Cyclosporine and azathioprine in clinically
relevant concentrations did not affect endothelial
repair. Thus, corticosteroids transiently inhibit
endothelial cytoskeletal alterations that are important
in endothelial repair after a denuding injury.
Key Words: cyclosporine A wound repair azathioprine endothelium corticosteroids
This article has been cited by other articles:
![]() |
M. K. Patricia, R. Natarajan, A. N. Dooley, F. Hernandez, J.-L. Gu, J. A. Berliner, J. J. Rossi, J. L. Nadler, R. S. Meidell, and C. C. Hedrick Adenoviral Delivery of a Leukocyte-Type 12 Lipoxygenase Ribozyme Inhibits Effects of Glucose and Platelet-Derived Growth Factor in Vascular Endothelial and Smooth Muscle Cells Circ. Res., April 13, 2001; 88(7): 659 - 665. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |